APA (7th ed.) Citation

Shah, N. P., García-Gutiérrez, J. V., Jiménez-Velasco, A., Larson, S., Saussele, S., Rea, D., . . . Lipton, J. H. (2019). DASFREE: Treatment-Free Remission (TFR) After Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR). Clinical lymphoma, myeloma & leukemia, 19, S299. https://doi.org/10.1016/j.clml.2019.07.253

Chicago Style (17th ed.) Citation

Shah, Neil P., et al. "DASFREE: Treatment-Free Remission (TFR) After Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)." Clinical Lymphoma, Myeloma & Leukemia 19 (2019): S299. https://doi.org/10.1016/j.clml.2019.07.253.

MLA (9th ed.) Citation

Shah, Neil P., et al. "DASFREE: Treatment-Free Remission (TFR) After Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)." Clinical Lymphoma, Myeloma & Leukemia, vol. 19, 2019, p. S299, https://doi.org/10.1016/j.clml.2019.07.253.